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Abstract A qualitative assessment of Kenyan men who
have sex with men taking daily and intermittent oral HIV pre-
exposure prophylaxis (PrEP) found stigma, sex work,
mobility, and alcohol impacted adherence. We analyzed
quantitative data from the same cohort to explore different
definitions of intermittent adherence. Volunteers were ran-
domized to daily emtricitabine/tenofovir or placebo, or
intermittent (prescription: Mondays/Fridays/after sex, maxi-
mum1dose/day) emtricitabine/tenofovir or placebo (2:1:2:1),
and followed for 4 months. By electronic monitoring, median
adherence for daily dosing was 80 %. Median adherence for
intermittent dosing was 71 % per a ‘‘relaxed’’ definition
(accounting for off-prescription dosing) and 40 % per a
‘‘strict’’ definition (limited to the prescription). Factors asso-
ciatedwith lower adherence included travel, transactional sex,
and longer follow-up; higher adherence was associated with
daily dosing and an income. The definition of intermittent
dosing strongly affects interpretation of adherence. These
findings suggest interventions should address challenges of
mobility, sex work, and long-term PrEP.
Keywords HIV  Pre-exposure prophylaxis  Intermittent
PrEP adherence  Men who have sex with men
Introduction
About 2.3 million people are newly infected with HIV
every year globally [1]. In Kenya, up to 15 % of new
infections occur among men who have sex with men
(MSM), and the HIV prevalence among MSM (15 %) is
twice that in the general population [2]. Cohort studies in
Kenya have documented a very high HIV incidence among
MSM. A multi-center cohort study documented an inci-
dence of 6.8 cases per 100 person-years of observation,
which was more than double the incidence among women
and heterosexual men in the same cohorts [3]. In a later
analysis at one of the centers, incidence among men who
have sex with men exclusively was 35.2 cases per 100
person-years compared to 5.8 per 100 person-years among
men who have sex with men and women [4]. Despite the
high HIV burden, engagement of MSM in research and
care is hampered by stigma and discrimination, and the fact
that male same sex behavior is criminalized in Kenya, as in
many other African countries [5]. However, interventions
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for MSM are now a key priority in the Kenyan national
HIV strategic plan [6].
Pre-exposure prophylaxis (PrEP), the administration of
antiretroviral medications (ARVs) to at-risk HIV-negative
persons to prevent HIV acquisition, has been shown to be
effective. In the iPrEx trial among MSM and transgender
women, a 44 % relative reduction in risk of HIV acqui-
sition was seen among participants randomized to use
daily oral emtricitabine/tenofovir versus placebo [7].
Efficacy was higher in two other trials of daily emtricit-
abine/tenofovir: 75 % among serodiscordant heterosexual
couples in the Partners PrEP trial conducted in Kenya and
Uganda [8] and 62 % among heterosexual men and
women in the TDF2 trial conducted in Botswana [9].
Daily Tenofovir tablets alone achieved an efficacy of
67 % in the Partners PrEP trial [8] and 49 % in the
Bangkok Tenofovir study conducted among injecting drug
users in Thailand [10]. In contrast, daily PrEP did not
show efficacy in the FEM-PrEP and VOICE trials con-
ducted among high-risk women in Eastern and Southern
Africa countries. However, analysis of drug levels pointed
to low adherence as the likely cause of the lack of effi-
cacy [11–13]. No significant safety concerns with daily
use of emtricitabine/tenofovir tablets were reported in any
of the above studies. Overall, higher efficacy was con-
sistently seen among volunteers with higher adherence.
Based on the results of the iPrEx and Partners trials, the
emtricitabine/tenofovir combination tablet was approved
for PrEP use in the United States, and guidelines for
clinical use released by the WHO [14]. In South Africa,
clinical guidelines have been developed, but regulatory
approval is pending [15].
Several post-trial access studies and demonstration
projects are currently underway [16, 17]. A secondary
analysis of the iPrEx trial showed that the greatest reduc-
tion in HIV transmission would be achieved if PrEP is
targeted toward MSM and transgender women reporting
unprotected receptive anal intercourse, cocaine use, or
sexually transmitted infections [18]. A PrEP demonstration
project in the US reported high interest in PrEP among
MSM attending a sexually transmitted disease clinic [19]
and an open label extension of the iPrEx study found high
PrEP uptake coupled with high protection that increased
with increasing levels of adherence [20]. A recent sys-
tematic review of mathematical modeling studies has found
PrEP to be most cost-effective when targeted at ‘‘key
populations at the highest risk of HIV exposure’’ [21].
To address concerns about long-term toxicity, adherence,
and cost of daily oral PrEP, efficacy of less-than-daily
dosing has been assessed in animal and mathematical
models. In the macaque model, various forms of intermittent
oral administration achieved 100 % efficacy, including 2 h
before and 24 h after a weekly virus challenge [22], as well
as 1, 3, or 7 days before exposure followed by a second dose
2 h after exposure [23]. A mathematical modeling study
using data from the iPrEx trial showed that two doses per
week would correspond to a 76 % reduction in HIV infec-
tions, while four and seven doses a week would correspond
to 96 and 99 % reduction, respectively [24]. In October
2014, the IPERGAY trial announced interim results showing
efficacy of intermittent PrEP, resulting in discontination of
the placebo arm.
Prior to the release of results from any of the PrEP trials,
a phase I/II randomized controlled trial of intermittent oral
PrEP was conducted in 2009–2010 among MSM in Kenya
[25]. In this trial, the prescription for intermittent dosing
was to take one tablet twice weekly on Mondays and Fri-
days and within 2 hours after sex, occurring on other days.
The study documented an excellent overall safety profile
for both daily and intermittent regimens. Using the medi-
cation event monitoring system (MEMS), lower adherence
was seen in the intermittent regimen compared to the daily
regimen (68 vs. 83 %), particularly with regard to post-
coital doses (26 %). Qualitative assessments revealed that
most trial volunteers favored intermittent dosing, but that
adherence to both daily and intermittent regimens was
hampered by stigmatizing effects of PrEP use, sex work,
mobility, and alcohol use [26].
In the primary analysis [25], intermittent adherence was
defined as MEMS openings strictly per the above-noted
prescription. Openings on days other than Mondays, Fri-
days, and on days with no reported sex were considered as
non-adherence. Volunteers who would not strictly follow
this relatively complex, calendar plus activity-based, regi-
men would have low calculated adherence. However,
considering emerging evidence that efficacy of PrEP may
be more dependent on overall number of doses per week
[24], such individuals may still have taken PrEP in a way
that affords protection against HIV. A more relaxed defi-
nition may not only predict efficacy more accurately, but it
also allows for variation in individual behaviors, prefer-
ences, and challenging life circumstances. Better under-
standing of dosing patterns and the factors that may
influence both daily and intermittent adherence will be
critical in optimizing use of PrEP in real-life settings.
In the analysis presented here, we use data from the
same Kenyan trial to further characterize adherence
behavior by assessing factors associated with adherence to
daily and intermittent regimens, and exploring the impact
of different definitions of intermittent adherence.
AIDS Behav (2015) 19:794–801 795
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Methods
Study Setting and Ethics Statement
Data for this study came from a randomized, placebo
controlled blinded trial of oral PrEP (Clinical trials.gov
number NCT00971230), conducted at two centers in
Kenya: Kenya AIDS Vaccine Initiative [KAVI]-Kangemi
in Nairobi, and KEMRI Center for Geographic Medicine
Research-Coast [CGMRC] in Kilifi. The study was spon-
sored by the International AIDS Vaccine Initiative (IAVI)
and approved by the Kenyatta National Hospital Ethics
Review Committee, the Kenya Medical Research Institute
National Ethics Review Committee and the Kenya Phar-
macy and Poison’s Board (Ministry of Health).
Volunteers
Trial volunteers were recruited from ongoing HIV pre-
vention cohorts at the two centers, which enroll MSM and
female sex workers [3]. Cohort volunteers attend monthly
or quarterly clinic visits where they access HIV testing and
risk reduction counseling, male condoms and water-based
lubricants, screening and treatment of sexually transmitted
infections, and referral for adult male circumcision for men
practicing heterosexual sex. Volunteers with at least
3 months of follow-up in the cohorts were enrolled. In
Kilifi, five women were included to avoid community
identification of the study as MSM-exclusive. However,
women were excluded from the current analysis given the
significant socio-behavioral differences compared to MSM.
Study Procedures
Detailed procedures for the trial are described elsewhere
[25]. Briefly, volunteers were randomized to either daily
self-administration of oral emtricitabine/tenofovir or pla-
cebo, or intermittent self-administration of oral emtricita-
bine/tenofovir or placebo (in a 2:1:2:1 ratio), and followed
monthly for 4 months. Adherence data were collected by
the Medication Event Monitoring System (MEMS), in
which each opening of the pill bottle was recorded elec-
tronically on the bottle cap, and by a face-to-face timeline
followback interview calendar (FBIC), in which pill taking
in the prior month was reviewed during an interview [27].
Volunteers were given a key chain pill holder in which they
were instructed to load a few pills when they were unable
or did not wish to carry the MEMS bottle. Curiosity
openings (i.e., bottle openings with no pills taken out) and
pocket doses (i.e., extra pills taken out for carrying in the
pill holder) were assessed at the FBIC interviews. To assess
adherence to post-coital doses, sexual activity data were
collected via daily Short Message Service (SMS) queries,
as well as through the FBIC.
Definitions and Statistical Analyses of Adherence
Monthly adherence to daily regimen was calculated as the
number of MEMS openings (i.e., number of doses taken)
divided by 28 (i.e., the number of doses expected over the
monitoring period). Monthly adherence to intermittent
regimen was calculated by two methods: strict i.e. per
prescription, and relaxed i.e. allowing some off-prescrip-
tion doses (Table 1). Off-prescription dosing could occur,
for example, if a volunteer took a forgotten Monday dose
on a Tuesday on which sex did not occur. The relaxed
adherence calculation counts that dose in the numerator,
while the strict adherence ignores it. Hence when more
doses are taken off-prescription, the relaxed method results
in higher adherence compared to the strict method. For the
primary analyses of this paper the relaxed definition of
intermittent adherence was used, while for secondary
analyses the strict definition was used.
Although the denominators are different for the inter-
mittent and daily adherence measures, the use of percent
adherence allowed for comparative and combined analyses.
We compared overall adherence levels over the 4-month
period among treatment and dosing groups using the Wil-
coxon rank-sum test. Using descriptive methods, we cal-
culated the number of volunteers with [80 % overall
adherence, a cut-off that has been used in prior studies to
categorize adherence, i.e. low or high, though not a firm
efficacy threshold [28]. Counting total number of MEMS
openings, corresponding to the relaxed definition for
intermittent dosing, we calculated the proportion of vol-
unteers who took four or more doses per week and the
median number of doses taken per week.
Potential factors associated with monthly adherence
over the four-month study period were examined via uni-
variable and multivariable linear repeated measures mod-
els. Data from all volunteers regardless of regimen were
assessed together. Baseline variables evaluated were: dos-
ing regimen (daily versus intermittent), age, years of edu-
cation, source of income, financial care of dependents,
engagement in sex work, and sex with men in month prior
to enrollment. Variables evaluated as time-varying covar-
iates (measured monthly over the four-month follow-up
period) were: any sex, number of sexual partners, any
occurrence of sex while drunk, sex with a new partner,
\100 % condom use with new or HIV ? partners,
involvement in transactional sex, receptive or insertive anal
intercourse or\100 % condom use with anal intercourse,
frequent travel (more than three nights on average per
week), any alcohol use, any drug use, and duration of
follow-up.
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All variables with p\ 0.10 from the univariable model
were included in an initial multivariable model. Subse-
quently, variables with p C 0.10, except dosing regimen in
which we had an a priori interest, were excluded, the model
was then re-fit and all interactions examined. A two-sided
p value of \0.05 was considered to indicate statistical
significance. Statistical analyses were performed with the
use of SAS software, version 9.2 (SAS Institute, Cary, NC,
USA).
Results
Sixty-two MSM (34 in Nairobi and 28 in Kilifi) who had
at least 1 month of follow-up in the trial were included
in the analyses. Table 2 presents their characteristics at
enrolment and during the four-month follow-up period.
Adherence by Treatment and Dosing Group
Because there was no difference in levels of adherence
between placebo and active treatment groups (data not
shown), the two were combined for all subsequent analyses.
Median [interquartile range, IQR] adherence over the
four-month follow-up period was 80 % [63–88 %] for the
daily dosing group and 71 % [51–99 %] for the intermit-
tent dosing group, using the relaxed definition (p = 0.81).
Using the strict definition, adherence to intermittent dosing
was 40 % [21–51 %] (p\ 0.0001, comparing with the
daily dosing group).
Fifteen (52 %) volunteers in the daily group had[80 %
adherence. In the intermittent group, 14 (42 %) volunteers
had adherence[80 % under relaxed definition, and under
strict definition only one volunteer (3 %) had adherence
[80 %. The proportion of volunteers with four or more
doses per week was 86 % (25/29) in the daily group and
3 % (1/33) in the intermittent group. Median MEMS
openings per week was 5.6 [4.4–6.1] in the daily group and
2.1 [1.3–2.7] in the intermittent group.
Factors Associated with PrEP Adherence
In the multivariate model combining daily and relaxed
intermittent adherence, lower adherence was significantly
associated with frequent travel in the past month and
marginally associated with transactional sex in the past
Table 1 Formulas used in calculation of different monthly adherence measures based on 28-day monitoring periods
Adherence to daily dosing ¼ Total number of MEMS openings
28 days
Strict adherence to intermittent dosing ¼
Number of MEMS openings on Mondays and Fridaysð Þ þ ðNumber of
MEMS openings on other days on which sex was reported by FBICaÞ
ðMondays and FridaysÞ þ ðNon - Mondays and Non - Fridays on which
sex was reported by FBICaÞ
Relaxed adherence to intermittent dosing ¼ Total number of MEMS openings
Mondays and Fridaysð Þ þ ðNon - Mondays and Non - Fridays on which
sex was reported by FBICaÞ
a Follow back interview calendar (FBIC) sexual activity data were used in preference to SMS data due to concerns about the reliability of SMS
data resulting from frequent mobile network outages during the study period
Table 2 Enrolment and follow-up characteristics of volunteers ran-
domized to daily versus intermittent dosing
Characteristics at enrolment Daily Intermittent
Number of volunteers 29 33
Mean age in years (range) 26
(20–38)
26 (18–35)
Mean years of education (range) 10 (0–16) 10 (0–15)
Source of income
Self (%) 62 61
Family (%) 24 15
No employment (%) 14 24
Married, monogamous (%) 0 6
Engaged in sex work in past month (%) 48 48




Any sex (%) 89 94
Any sex while drunk (%) 36 44
Sex with a new partner (%) 65 65
\100 % condom use with new or HIV ? partners (%) 34 17
Involved in transactional sex (%) 63 63
Sex with a known HIV ? person (%) 1 2
Receptive anal intercourse (%) 54 60
Insertive anal intercourse (%) 62 60
\100 % condom use with anal intercourse (%) 36 34
Frequent travel (%) 40 44
Any alcohol use (%) 54 69
Any drug use (%) 40 52
a Average event rate per month, based on events reported for 114 and
126 follow-up months for daily and intermittent groups, respectively
AIDS Behav (2015) 19:794–801 797
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month (Table 3). Dosing regimen (daily versus intermit-
tent) did not show any significant association with PrEP
adherence.
In the secondary analysis, where the strict definition for
intermittent adherence was used (Table 4), transactional
sex in the past month, and longer time on study (per each
additional month of follow-up) were associated with lower
adherence; a marginal association was also seen with fre-
quent travel in the past month. Daily dosing (versus
intermittent dosing) and self/family income (versus no
employment) were associated with higher adherence; a
marginal association was also seen with sex with a new
partner in the past month.
The large difference in adherence between dosing
groups in the secondary analysis prompted further analysis
of each dosing group separately to determine if factors may
be uniquely associated with adherence to each dosing
regimen (see Supplementary Tables I to III). In the mul-
tivariate model for the daily dosing group only, lower
adherence was significantly associated with frequent travel
(p = 0.01) and marginally associated with any occurrence
of sex while drunk (p = 0.06). Frequent travel in the past
month was the only factor marginally associated with a
lower adherence to intermittent PrEP, using the relaxed
definition (p = 0.07). Using the strict definition, lower
adherence to intermittent PrEP was associated with trans-
actional sex in the past month (p = 0.03) and longer time
on study (p = 0.03), while higher adherence was associ-
ated with self/family income (versus no employment)
(p = 0.04). A summary of factors associated with PrEP
adherence is presented in Table 5.
Discussion
In this analysis of a randomized clinical trial of daily and
intermittent PrEP among Kenyan MSM, we found that the
definition of intermittent adherence significantly affects
interpretation of adherence behavior. As in our previous
report of this trial, intermittent adherence as defined strictly
Table 3 Factors associated with adherence to PrEP for combined daily and relaxed intermittent dosing groups
Factor Univariable analysis Multivariable analysis
Estimate p value Estimate p value
Age (per year) 1.0 0.13 – –
Years of education 0.6 0.46 – –
Source of income 0.48 – –
Self 9.6 0.23 – –
Family 6.0 0.54 – –
No employment Reference N/A – –
Financial care of dependents 3.0 0.68 – –
Engaged in sex work in month prior to enrollment -7.2 0.24 – –
Had sex with men in month prior to enrollment 0.9 0.92 – –
Any sexa -19.4 0.02 – –
# Sexual partnersa 0.2 0.72 – –
Any occurrence of sex while drunka -6.2 0.18 – –
Sex with a new partnera 1.6 0.71 – –
\100 % condom use with new or HIV ? partnersa 1.2 0.80 – –
Involved in transactional sexa -8.7 0.08 -8.7 0.07
Receptive anal intercoursea -4.1 0.42 – –
Insertive anal intercoursea 4.6 0.35 – –
\100 % condom use with anal intercoursea -2.7 0.60 – –
Frequent travela -9.8 0.01 -9.2 0.01
Any alcohol usea -0.8 0.86 – –
Any drug usea -4.8 0.38 – –
Duration on study (per study month)a -4.3 0.01 – –
Daily Dosing Regimenb 2.2 0.72 5.9 0.30
Estimates should be interpreted as percentage point changes from the reference factor
a Time-varying covariate (measured monthly)
b Daily dosing regimen was retained in the multivariate model due to a priori interest
798 AIDS Behav (2015) 19:794–801
123
by the prescribed regimen was significantly lower than
daily adherence. No significant difference, however, was
seen when a relaxed definition of intermittent dosing was
used. Other factors associated with PrEP adherence varied
to some extent depending on the definition of intermittent
adherence; however, frequent travel and transactional sex
consistently appeared as factors associated with lower
adherence. Using the strict definition, longer duration of
PrEP use was also associated with lower adherence, and a
source of income (versus no employment) was associated
with higher adherence.
Similar to our earlier qualitative assessments [26], the
current analysis suggests that adherence interventions
should address challenges related to mobility, sex work,
and long-term PrEP. The best design for interventions to
tackle these challenges is not clear. One potential approach
would be to use counseling tailored to mobility, sex work,
and long-term PrEP. Tailored counseling has been used in
clinical trials [29, 30] and appears promising, but strategies
for ‘‘real world’’ settings need further development. Effects
of frequent travel could also be addressed by distributing
PrEP widely so that MSM can access emergency supply
when away from their usual residence.
This analysis highlights the complexities in defining and
measuring adherence to an intermittent PrEP regimen. A
greater number of significant factors were seenwith the strict
definition, which may reflect the effects of individual
behaviors, preferences and circumstances that make adher-
ence more difficult. The relaxed adherence measure likely
accounts for strategies used by volunteers to take PrEP
despite the challenges they face. For example, theymay have
opened the MEMS bottle on non-prescribed days while
loading pills into keychain holders. Off-prescription dosing
may also have occurred due to forgetting or temporary lack
of access to the medication, leading to late dosing on a non-
prescribed day. Moreover, the relaxed definition also
accounts for possible limitations of the self-report follow-
back interview in ascertaining the exact days on which sex
occurred (i.e., some of the ‘‘off prescription’’ doses may
actually have been taken on days when sex occurred, but day
of sex was not reported accurately). An increase in sex
reporting over the study period was noted in our previous
Table 4 Factors associated with adherence to PrEP for combined daily and strict intermittent dosing groups
Factor Univariable analysis Multivariable analysis
Estimate p value Estimate p value
Age (per year) 0.7 0.35 – –
Years of education 0.8 0.41 – –
Source of income 0.04 0.03
Self 20.1 0.02 19.0 0.01
Family 22.6 0.03 18.8 0.04
No employment Reference N/A Reference N/A
Financial Care of Dependents -8.2 0.30 – –
Engaged in sex work in month prior to enrollment -6.3 0.35 – –
Had sex with men in month prior to enrollment -1.8 0.84 – –
Any sexa -8.9 0.19 – –
# Sexual partnersa 0.7 0.17 – –
Any occurrence of sex while drunka -8.8 0.03 – –
Sex with a new partnera 5.9 0.09 6.1 0.08
\100 % condom use with new or HIV ? partnersa 1.4 0.74 – –
Involved in transactional sexa -7.2 0.10 -10.2 0.02
Receptive anal intercoursea -5.3 0.25 – –
Insertive anal intercoursea 7.2 0.10 – –
\100 % condom use with anal intercoursea -2.2 0.64 – –
Frequent travela -7.4 0.02 -5.1 0.09
Any alcohol usea -3.3 0.41 – –
Any drug usea -4.4 0.41 – –
Duration on study (per study month)a -4.6 0.0003 -3.2 0.02
Daily Dosing Regimenb 25.9 \0.0001 26.7 \0.0001
Estimates should be interpreted as percentage point changes from the reference factor
a Time-varying covariate (measured monthly)
b Daily dosing regimen was retained in the multivariate model due to a priori interest
AIDS Behav (2015) 19:794–801 799
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paper and may explain the decrease in strict intermittent
adherence seen with longer duration on study [25].
A mathematical modelling study based on data from the
iPrEx trial showed that protection from HIV infection may
be correlated with a specific number of PrEP doses per
week, regardless of exact dosing intervals [24]. Extrapo-
lating this model to our trial data, 86 % of volunteers in the
daily group and 3 % in the intermittent group would have
received 99 % protection. This extrapolated finding is
concerning with regard to the intermittent dosing group. It
is also important to note that achieving four doses a week,
given the prescription based on sexual activity, would
require sex 2 days per week on a non-Monday and non-
Friday. Clinical efficacy data from the ongoing IPERGAY
and ADAPT [31, 32] studies will be essential in deter-
mining the efficacy of various intermittent PrEP regimens
at various adherence levels.
This study has limitations. First, our sample may have
been too small to identify all the factors that may influence
PrEP adherence. The factors we identified in this analysis
were largely the same as those identified through qualita-
tive assessment [26], although the comparison is limited by
use of a strict definition of adherence in selecting the
participants for that study. Second, the trial did not collect
data on some of the factors that may have an impact on
PrEP adherence, such as stigma, depression and risk per-
ception; hence, these were not included in the regression
analysis. Third, our findings with regard to the level of
adherence observed may not be generalizable to settings
where PrEP will be used for a longer time or where the
efficacy of PrEP is known. For example, transactional sex
may be associated with better post-coital adherence if PrEP
users are aware that it would protect them. Lastly, our
understanding of intermittent adherence using a relaxed
definition was based on hypothesized use patterns in vol-
unteers instructed to follow a strict regimen; hence, this
measure may not predict the actual adherence levels if the
initial prescription was relaxed as well (i.e. if PrEP users
were told to take it when they could, as close as possible to
a twice weekly and post-coital regimen).
In conclusion, we found that while the definition of inter-
mittent dosing has a strong effect on interpretation of adher-
ence behavior, results confirm earlier qualitative findings and
suggest that adherence interventions should address chal-
lenges related to sex work, mobility, and long-term PrEP. As
researchers consider less frequent dosing to improve adher-
ence, careful assessment of adherence behavior is needed.
Acknowledgments We would like to acknowledge the contribu-
tions of the study volunteers to this research. We would like to thank
the research center staff in Kilifi and Nairobi. IAVI’s work is made
possible by generous support from many donors including: the Bill &
Melinda Gates Foundation; the Ministry of Foreign Affairs of Den-
mark; Irish Aid; the Ministry of Finance of Japan; the Ministry of
Foreign Affairs of the Netherlands; the Norwegian Agency for
Development Cooperation (NORAD); the United Kingdom Depart-
ment for International Development (DFID), and the United States
Agency for International Development (USAID). The full list of IAVI
donors is available at www.iavi.org. This paper was published with
permission from the Director of KEMRI.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. UNAIDS. Report on the global AIDS epidemic: Joint United
Nations Programme on HIV/AIDS (UNAIDS). 2013.
Table 5 Summary of factors associated with PrEP adherence for different dosing groups and adherence definitions













Factors associated with higher adherence
Daily dosing (vs intermittent dosing) – :* n/a n/a n/a
Self/family income (vs no employment) – :* – – :*
New sex partner – : – – –
Factors associated with lower adherence
Frequent travel ;* ; ;* ; –
Transactional sex ; ;* – – ;*
Longer duration of follow-up (per study month) – ;* – – ;*
Sex while drunk – – ; – –
:* denotes significantly higher adherence (p\ 0.05), : denotes marginally higher adherence (p\ 0.1), ;* denotes significantly lower adherence,
; denotes marginally lower adherence, ‘‘–’’ denotes no association, and ‘‘n/a’’ means not applicable
800 AIDS Behav (2015) 19:794–801
123
2. Beyrer C, Baral SD, Walker D, Wirtz AL, Johns B, Sifakis F. The
expanding epidemics of HIV type 1 among men who have sex
with men in low- and middle-income countries: diversity and
consistency. Epidemiol Rev. 2010;32(1):137–51.
3. Price MA, Rida W, Mwangome M, et al. Identifying at-risk
populations in Kenya and South Africa: HIV incidence in cohorts
of men who report sex with men, sex workers, and youth.
J Acquir Immune Defic Syndr. 2012;59(2):185–93.
4. Sanders EJ, Okuku HS, Smith AD, et al. High HIV-1 incidence,
correlates of HIV-1 acquisition, and high viral loads following
seroconversion among MSM. AIDS. 2013;27(3):437–46.
5. Smith AD, Tapsoba P, Peshu N, Sanders EJ, Jaffe HW. Men who
have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet.
2009;374(9687):416–22.
6. KNACC. Kenya National AIDS Strategic Plan 2009–2013:
Kenya National AIDS Control Council. 2009.
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemo-
prophylaxis for HIV prevention in men who have sex with men.
N Engl J Med. 2010;363(27):2587–99.
8. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis
for HIV prevention in heterosexual men and women. N Engl J
Med. 2012;367(5):399–410.
9. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral
preexposure prophylaxis for heterosexual HIV transmission in
Botswana. N Engl J Med. 2012;367(5):423–34.
10. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral
prophylaxis for HIV infection in injecting drug users in Bangkok,
Thailand (the Bangkok Tenofovir Study): a randomised, double-
blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):
2083–90.
11. Van Damme L, Corneli A, Ahmed K, et al. Preexposure pro-
phylaxis for HIV infection among African women. N Engl J Med.
2012;367(5):411–22.
12. MTN. Daily HIV prevention approaches didn’t work for African
women in the VOICE study. Pittsburgh: Microbicide Trials
Network; 2013.
13. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR.
Unraveling the divergent results of pre-exposure prophylaxis
trials for HIV prevention. AIDS. 2012;26(7):F13–9.
14. WHO. Guidance on Pre-exposure oral prophylaxis (prep) for
serodiscordant couples, men and transgender women who have
sex with men at high risk of HIV. Geneva: World Health Orga-
nization; 2012.
15. SAHCS. Southern African guidelines for the safe use of pre-
exposure prophylaxis in men who have sex with men who are at
risk for HIV infection. The Consensus Committee, Southern
African HIV Clinicians Society; 2012.
16. AVAC. PrEP research to rollout: a schematic road map. AVAC;
2011.
17. AVAC. Ongoing and planned PrEP trials and demonstration
projects as of August 2013. AVAC; 2013.
18. Buchbinder SP, Glidden DV, Liu AY, et al. HIV pre-exposure
prophylaxis in men who have sex with men and transgender
women: a secondary analysis of a phase 3 randomised controlled
efficacy trial. Lancet Infect. Dis. 2014; 14(6):468–475.
19. Liu A, Cohen S, Follansbee S, et al. Early experiences imple-
menting pre-exposure prophylaxis (PrEP) for HIV prevention in
San Francisco. PLoS Med. 2014;11(3):e1001613.
20. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-
exposure prophylaxis, sexual practices, and HIV incidence in
men and transgender women who have sex with men: a cohort
study. Lancet Infect Dis. 2014;14(9):820–9.
21. GomezGB,BorquezA,CaseKK,WheelockA,Vassall A,Hankins
C. The cost and impact of scaling up pre-exposure prophylaxis for
HIV prevention: a systematic review of cost-effectiveness model-
ling studies. PLoS Med. 2013;10(3):e1001401.
22. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal
SHIV transmission in macaques by daily or intermittent prophy-
laxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):e28.
23. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent pro-
phylaxis with oral truvada protects macaques from rectal SHIV
infection. Sci. Transl. Med. 2010;2(14):14ra14.
24. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir
concentrations and pre-exposure prophylaxis efficacy in men who
have sex with men. Sci. Transl. Med. 2012;4(151):151ra125.
25. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to
intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in Afri-
can men who have sex with men and female sex workers. PLoS
ONE. 2012;7(4):e33103.
26. Van der Elst EM, Mbogua J, Operario D, et al. High acceptability
of HIV pre-exposure prophylaxis but challenges in adherence and
use: qualitative insights from a phase I trial of intermittent and
daily PrEP in at-risk populations in Kenya. AIDS Behav.
2012;17(6):2162–2172.
27. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the
alcohol timeline followback when administered by telephone and
by computer. Drug Alcohol Depend. 1996;42(1):49–54.
28. Haberer JE, Baeten JM, Campbell J, et al. Adherence to anti-
retroviral prophylaxis for HIV prevention: a substudy cohort
within a clinical trial of serodiscordant couples in East Africa.
PLoS Med. 2013;10(9):e1001511.
29. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten
A. Adherence support approaches in biomedical HIV prevention
trials: experiences, insights and future directions from four mul-
tisite prevention trials. AIDS Behav. 2013;17(6):2143–55.
30. Psaros C. Evaluation and Process Outcomes from an adherence
intervention to support HIV pre-exposure prophylaxis (PrEP)
adherence in HIV-serodiscordant couples in Uganda. Paper pre-
sented at: 7th International Conference on HIV Treatment and
Prevention Adherence. Miami: 2012.
31. ClinicalTrials.gov. On demand antiretroviral pre-exposure pro-
phylaxis for HIV infection in men who have sex with men
(IPERGAY). http://clinicaltrials.gov/ct2/show/NCT01473472
(2013). Accessed 02 Oct 2014.
32. ClinicalTrials.gov. The ADAPT study: use of emtricitabine and
tenofovir disoproxil fumarate for pre-exposure prophylaxis
(PrEP). http://clinicaltrials.gov/ct2/show/NCT01327651?term=
adapt&rank=7 (2014). Accessed 02 Oct 2014.
AIDS Behav (2015) 19:794–801 801
123
